2019
Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States
Huntington S, Soulos P, Barr P, Jacobs R, Lansigan F, Odejide O, Schwartzberg L, Davidoff A, Gross C. Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States. Blood 2019, 134: 797. DOI: 10.1182/blood-2019-122054.Peer-Reviewed Original ResearchFirst-line settingChronic lymphocytic leukemiaFlatiron Health databaseECOG performance statusFirst-line treatmentEarly discontinuationMultivariable logistic regressionPerformance statusIbrutinib discontinuationSpeakers bureauClinical trialsCLL diagnosisCLL therapyLymphocytic leukemiaHealth databasesLogistic regressionBruton tyrosine kinase inhibitorsFirst-line ibrutinibUse of ibrutinibWorse performance statusPoor performance statusRetrospective cohort studyCommunity oncology settingClinical decision support toolCommunity oncology practices
2017
Physician volume and discontinuation of rituximab during lymphoma treatment.
Huntington S, Long J, Hoag J, Wang R, Zeidan A, Giri S, Gore S, Ma X, Gross C, Davidoff A. Physician volume and discontinuation of rituximab during lymphoma treatment. Journal Of Clinical Oncology 2017, 35: 6593-6593. DOI: 10.1200/jco.2017.35.15_suppl.6593.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaEarly discontinuationRituximab discontinuationPhysician volumeProvider volumeEnd Results-Medicare dataB-cell non-Hodgkin lymphomaCell non-Hodgkin lymphomaCox proportional hazards modelDiscontinuation of rituximabSevere infusion reactionsRetrospective cohort studyImpact of discontinuationDays of initiationProportional hazards modelDose-dependent mannerRituximab cyclesRituximab initiationInfusion reactionsOverall survivalCohort studyPrimary outcomeSystemic treatmentLymphoma treatmentRelative risk
2012
Predictors of early discontinuation of chemotherapy (EDC) in patients (pts) age 65 or older with stage IV non-small cell lung cancer (NSCLC).
Gajra A, Tew W, Hardt M, Mohile S, Owusu C, Klepin H, Gross C, Lichtman S, Katheria V, Hurria A. Predictors of early discontinuation of chemotherapy (EDC) in patients (pts) age 65 or older with stage IV non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2012, 30: e18133-e18133. DOI: 10.1200/jco.2012.30.15_suppl.e18133.Peer-Reviewed Original ResearchStage IV non-small cell lung cancerNon-small cell lung cancerPoor physical functionOlder ptsPhysical functionAge 65Multi-site prospective studyBivariate analysisGeriatric assessment variablesPatients age 65Cell lung cancerMultivariate logistic regressionLower mean HbPt ageChemotherapy toxicityEarly discontinuationAlbumin levelsMean HbProspective studyPoor outcomeHigher cancerLung cancerPhysical scoresSubset analysisDisease progression